Navigation Links
Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
Date:1/4/2008

- VELCADE(R) (bortezomib) for Injection sales grew 20% to $265 million in

2007- - sNDA submitted for VELCADE expansion into front-line multiple myeloma - - MLN0002 core bridging studies fully enrolled, showing favorable results -

- New proteasome inhibitor, MLN2238, enters development pipeline -

- On track to exceed 2007 net income financial guidance -

CAMBRIDGE, Mass., Jan. 4 /PRNewswire-FirstCall/ -- Building on a record year in 2007, Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced 2008 corporate goals and financial guidance. These goals, along with selected financial and operational results from 2007, will be presented at the 26th Annual JPMorgan Healthcare Conference on January 9, 2008, in San Francisco, Calif.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"The past year was the most successful in the Company's 15-year history with outstanding accomplishments across commercial, R&D and operations. Millennium is well positioned for strong growth in 2008 and beyond," said Deborah Dunsire, M.D., President and Chief Executive Officer, Millennium. "The expected launch in front-line multiple myeloma is the next catalyst for VELCADE. Our late-stage product candidate, MLN0002, is approaching pivotal trials in inflammatory bowel diseases, representing the next revenue growth driver, and our innovative R&D organization continues to fuel the pipeline. We begin 2008 in the strongest financial position in the Company's history and remain firmly committed to continued top- and bottom-line growth."

In 2008, the Company's goals will focus on three strategic
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
2. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
3. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
4. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
5. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
6. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
7. Life Sciences Leader Joins Millennium Board of Directors
8. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
9. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
10. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
11. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... An increase of awareness related to benefits of ... nutrients, regulatory changes and concerns related to consumer safety ... natural astaxanthin over the past few years. Producers of ... to satisfy the rising demand. , The global ... in nutraceuticals, aqua feed, food and beverages and cosmetics) ...
(Date:3/25/2015)... 2015 Data from Evidence of ... Action in Neuromuscular Diseases , South San ... (Nasdaq: CYTK) announced the publication of a manuscript ... tirasemtiv in the journal Neurotherapeutics. This publication ... Effect” or hypothesis-generating clinical trial which evaluated tirasemtiv ...
(Date:3/25/2015)... 2015 Researchers at Ancon Medical ... that will enable broader and less invasive screening ... a simple breath screen. The Minnesota-based medical device ... and Drug Administration (FDA) approval process and is ... Nanoparticle Biomarker Tagging device. , Ancon Medicals nanoparticle ...
(Date:3/25/2015)... 2015  The Technology Association of Georgia ... the promotion and economic advancement of Georgia,s ... one of its Top 40 Innovative Technology Companies in ... prestigious group at the 2015 Georgia Technology Summit (GTS) ... TAG,S Top 40 Awards recognize ...
Breaking Biology Technology:Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 2Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 3Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 4
... DIEGO, Nov. 6 Halozyme Therapeutics, Inc.,(Nasdaq: ... targeting the extracellular matrix for the drug delivery,endocrinology, ... the three and nine months ended September 30, ... been stronger and I am,pleased with the initiation ...
... 6 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President,and CEO of ... a,corporate overview of the Company at the Rodman & ... at 11:10 a.m. ET. The,event will be held at ... A live audio webcast of the presentation will ...
... Highlights:, * Submitted NDA with FDA for NGX-4010 for management of pain ... ... EMEA,s scheduled Day 120 questions regarding MAA under ... SAN MATEO, Calif., Nov. 6 NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical ...
Cached Biology Technology:Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 2Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 3Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 4Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 5Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 6Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 7Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 8Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference 2NeurogesX Reports Third Quarter 2008 Results 2NeurogesX Reports Third Quarter 2008 Results 3NeurogesX Reports Third Quarter 2008 Results 4NeurogesX Reports Third Quarter 2008 Results 5NeurogesX Reports Third Quarter 2008 Results 6NeurogesX Reports Third Quarter 2008 Results 7NeurogesX Reports Third Quarter 2008 Results 8NeurogesX Reports Third Quarter 2008 Results 9
(Date:3/5/2015)... PAULO , March 5, 2015 In ... 41 percent of companies already using these solutions and 42 ... 2015. Of the latter, approximately 25 percent of the companies ... While the majority of companies in the region ... anticipated that the hybrid model will command significant attention in ...
(Date:3/2/2015)... March 2, 2015 Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new implementation ... to enable rapid and secure transactions and reliable ... gaming is a turnkey solution providing mouse and ... quickly integrate fingerprint ID solutions into their product ...
(Date:2/25/2015)... 25, 2015  ABC Financial Services (ABC), the ... Health and Fitness Industry, today announced enhancements to ... The latest upgrade includes advances to the agreement ... check-in via Identity One fingerprint biometrics. The features ... interactive displays at the International Health, Racquet & ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... to remove contaminants from soil, scientists at the ... and their Belgium colleagues at Hasselt University have ... on marginal land. The findings, published in the ... Environmental Microbiology , may help scientists design strategies ...
... the FDA has approved the first human clinical trial ... considerations, but not only, or even primarily, because what ... Although deep-seated disagreements about the ethics of embryo ... to focus as well on this being the first ...
... (ACMG) will hold its 16th Annual Clinical Genetics Meeting ... at the Tampa Convention Center. Clinical and medical ... a dizzying pace and the 2009 ACMG Annual Clinical ... and scientific media to learn firsthand about the latest ...
Cached Biology News:Scientists identify bacteria that increase plant growth 2Scientists identify bacteria that increase plant growth 3Far-reaching genetics topics to be addressed: 2009 Annual Clinical Genetics Meeting, March 25-29 2
... series of refrigerated cold traps offers a ... low volatility/aqueous solvents or high volatility solvents. ... vacuum concentrators/centrifugal evaporators. Also used for maintaining ... as used in electron microscopes. Can be ...
Black 96 Well Plate EB, RE Bottom...
... Tabletop orbital shakers combine high durability and ... patented triple-counterbalanced heavy-duty mechanism prevents vibration, allowing ... out-of-balance loads. Every other part, from the ... the thick machined aluminum platform is designed ...
...
Biology Products: